Skip to main content
GeneOne Life Science, Inc. logo

GeneOne Life Science, Inc. — Investor Relations & Filings

Ticker · 011000 ISIN · KR7011000007 KO Professional, scientific and technical activities
Open in API
Filings indexed 490 across all filing types
Latest filing 2025-12-23 Capital/Financing Update
Country KR South Korea
Listing KO 011000

About GeneOne Life Science, Inc.

https://www.genels.com/en/

GeneOne Life Science, Inc. is a biopharmaceutical research and development company specializing in nucleic acid-based biomedicines. The company's core focus is on developing DNA and mRNA vaccines, particularly for emerging infectious diseases, leveraging its rapid development platforms. In therapeutics, GeneOne utilizes a proprietary DNA plasmid delivery technology to enable the expression of recombinant proteins and plasmid-encoded monoclonal antibodies (Plas-mAbs®). This non-viral vector approach is designed to offer a safer and more cost-effective alternative to traditional gene therapies and cell-line derived monoclonal antibody treatments for conditions such as cancers and autoimmune disorders. The company also develops immunomodulatory small molecule drugs. Through its subsidiary, GeneOne possesses cGMP-grade manufacturing capabilities for DNA plasmids, supporting its internal pipeline and contract manufacturing services.

Recent filings

Filing Released Lang Actions
[기재정정]유상증자신주발행가액(안내공시)
Capital/Financing Update Classification · 98% confidence The document is a regulatory filing from GeneOne Life Science regarding a 'Capital Increase' (Rights Offering) and specifically details the adjustment of the 'New Share Issuance Price'. It outlines the correction of the issuance price per share due to a change in the payment date. This falls under the category of capital structure changes and share issuance updates, which is best classified as 'SHA' (Share Issue/Capital Change).
2025-12-23 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정). It details the issuance of new shares, the purpose of the capital raise, the third-party allocation details, and the schedule for payment and listing. This is a regulatory filing concerning capital structure changes and share issuance, which falls under the 'Share Issue/Capital Change' category.
2025-12-23 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서(일반)' which translates to 'Report on Large Shareholding Status (General)'. It contains detailed information about shareholding changes, ownership percentages, and related contractual details. The document references specific dates and shareholding percentages, indicating it is a notification of changes in significant share ownership levels. There is no indication that this is an annual report, earnings release, or any other financial report. The content aligns with the definition of a Major Shareholding Notification, which involves reporting changes in significant share ownership levels crossing thresholds. Therefore, the document is best classified as a Major Shareholding Notification (MRQ).
2025-11-11 Korean
유상증자또는주식관련사채등의발행결과(자율공시)
Capital/Financing Update Classification · 100% confidence The document is a short announcement (651 characters) detailing the results of a capital raising event involving issuance of convertible bonds (a type of debt instrument). It includes specifics such as the type of security, issuance method, amount, dates, and references a prior announcement. There are no financial statements or detailed financial analysis present. The document is an update on financing activity, specifically the issuance results of convertible bonds, which fits the Capital/Financing Update category. It is not a full report, nor a regulatory certification or voting result. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-11-04 Korean
[기재정정]타인에대한채무보증결정
Capital/Financing Update Classification · 95% confidence The document is a disclosure about a decision to provide a guarantee for a third party's debt, including details such as the debtor, creditor, amount, guarantee period, and related financial information. It is a regulatory announcement related to a financial guarantee decision, not a full financial report or earnings release. The document length is short (2808 characters) and it is a specific announcement about a debt guarantee decision, which fits the category of Capital/Financing Update (CAP). There is no indication that this is a full report, audit, or management discussion, nor is it a voting result or legal proceeding. Therefore, the best classification is CAP with high confidence.
2025-10-29 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 95% confidence The document is a detailed disclosure regarding the issuance of convertible bonds (전환사채권 발행결정) by the company 진원생명과학(주). It includes specifics such as bond terms, conversion price adjustment mechanisms, early redemption options (Put option), issuance details, and related financial information. The document is addressed to regulatory bodies (Financial Services Commission and Korea Exchange) and contains detailed financial and contractual terms related to capital raising through convertible bonds. This fits the definition of a Capital/Financing Update (CAP), as it provides updates on company fundraising and capital structure changes. The document is lengthy (over 10,000 characters) and contains substantive financial and contractual details, not merely an announcement or a brief summary. Therefore, the appropriate classification is CAP with high confidence.
2025-10-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.